Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bivictrix Therapeutics Plc | BVX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.00 | 10.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 19/7/2023 20:01 by jane deer I see BVX doing a placing and subscription at 13p (below today's closing price of 15.9p). Directors and large shareholders were able to participate but ordinary shareholders are not - with no retail offer nor open offer. We see this story loads of times!!But what is interesting is that towards the end of the 19 July RNS on the Proposed Fundraise on under the section "RIGHT TO TERMINATE UNDER THE PLACING AGREEMENT", Condition 3 has the following language which indicates that an Open Offer was also planned. At least someone forgot to delete the term "Open Offer" from the final version. "if, amongst other things, there is a substantial change in any national or international political, military, diplomatic, economic, financial or market conditions which in the Joint Broker's opinion (acting in good faith and after such consultation with the Company or the other Joint Broker as shall be practicable in the circumstances) would have or be likely to have a material and adverse effect on the Placing, the Open Offer or dealings in Placing Shares in the secondary market or is of such magnitude to render the Placing or the creation of a market in the Placing Shares temporarily or permanently impracticable or inadvisable" |
Posted at 14/8/2021 00:25 by 40 fathoms Robert Keith, a serial backer of hi-tech companies, a former director of computer software company Eidos, and a major stakeholder in drug development company Silence Therapeutics PLC, among others. He tends to overlap a lot with Richard Griffiths and we know that he was looking to participate in the RTO, so maybe we should expect a TR1 from him as well.I think what they have spotted is that the BVX IPO, when compared to both the couple of US listed companies with Bispecific ADC products and to the recent licensing deals, which were all early stage, has been done at an incredibly attractive price. By this time next year there will be 3 ADC candidates in the pipeline and by the end of next year or there abouts they will all have some preclinical data. Assuming that data is good, there could easily be a licensing deal by the end 2023 for GBP 1 to 1.5 billion with GBP150 million to 250 million in upfront payments (a deal like that would be 100x the current market cap). Obviously high risk but very high rewards and initial realisation may well be before Phase I. |
Posted at 11/8/2021 14:16 by hedgehog 100 "Development Bank of Wales supports BiVictriX Therapeutics’ IPO on AIMPublished: 02/08/2021 BiVictriX Therapeutics (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience, has announced its intention to list on the AIM market of the London Stock Exchange/ BiVictriX is proposing to raise £7.5 million (before expenses) by way of a placing and subscription of new ordinary shares as part of its initial public offering (IPO). BiVictriX’s pioneering ‘precision&rsq As a component of the IPO, Iain Ross will join the board as Chair, together with experienced non-executive directors Susan Lowther and Drummond Paris. Professor Bob Hawkins, a world-renowned oncologist and biotech innovator completes the board and will add significant scientific support. Existing lead investor, the Development Bank of Wales, will make an additional £500,000 share purchase and remain the largest shareholder of the company. With BiVictriX’s listing on AIM, 33-year-old CEO Tiffany Thorn will become one of the youngest female CEOs of a UK-based publicly listed technology firm. CEO and Founder of BiVictriX, Tiffany Thorn, said: “This is an exciting step for all of us at BiVictriX. This fundraise will allow us to accelerate our growth and expedite the development and delivery of our next-generation, highly selective cancer therapeutics to patients diagnosed with some of the most difficult-to-treat cancers, in urgent need of more effective therapies. We would like to take this opportunity to offer our sincere gratitude and thanks to all of our supportive investors, both old and new, for their help in enabling us to carry out this crucial work.” Initially receiving seed investment in 2016, BiVictriX has been supported over multiple funding rounds by the Development Bank of Wales. Deputy Fund Manager Mike Bakewell said: “We’ve worked with BiVictriX and Tiffany Thorn for five years, investing seed equity finance as well as subsequent follow-on rounds as the company develops its lead therapeutic candidate. We believe in being a long-term partner to our high-growth technology companies. BiVictriX is developing a unique approach that will truly revolutionise treatment of hard-to-fight cancers like AML. We’re delighted to work with Tiffany and the team as they take their next steps with this AIM listing.” Development Bank of Wales Investment Director Rhian Elston said: “Tiffany and BiVictriX are leading the way in important medical research, as well as breaking down boardroom barriers to women in tech. Tiffany is a highly talented CEO and scientist and BiVictriX’s approach has the clear potential to develop next-generation cancer treatments. Having founded the company at 28 years old, just five years later she will now be one of the youngest female CEOs to list on AIM. She is a true trailblazer. As an investor, we’re committed to long-term partnerships – like our relationship with BiVictriX – and providing patient capital to support companies from seed to listing or exit.” BiVictriX will be fifth company the Development Bank of Wales technology venture investments team has supported to list on AIM." P.S. Thanks 40 Fathoms. |
Posted at 11/8/2021 09:37 by hedgehog 100 11/08/2021 08:24 UK Regulatory (RNS & others) BiVictriX Therapeutics PLC Admission to Trading on AIM & First Day Dealings LSE:BVX Bivictrix Therapeutics Plc"Alderley Park, UK, 11 August 2021: BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, is pleased to announce the admission of its entire issued and to be issued ordinary share capital (the "Ordinary Shares") to trading on the AIM market of the London Stock Exchange ("Admission"). The commencement of trading of the Company's Ordinary Shares follows a successful oversubscribed placing by share price Angel Corporate Finance LLP ("SP Angel"), raising gross proceeds of GBP7.5 million at a price of 20 pence per Ordinary Share. At Admission, the market capitalisation of the Company will be approximately GBP13.2 million. Dealings have commenced at 8.00 a.m. today under the ticker symbol "BVX" and the ISIN number GB00BNXH3K91. Tiffany Thorn, Chief Executive Officer and Founder of BiVictriX Therapeutics plc, said: "Today's listing on London's AIM market is a major milestone for BiVictriX. Our vision is to revolutionise cancer therapy for the most difficult to treat cancers, making curative treatments available to all. The funds raised will help us to accelerate our growth and expedite the development and delivery of our pioneering, highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers and supporting patients who are currently in urgent need of more effective medicines. "I would like to take this opportunity to offer our sincere gratitude and thanks to all of our staff, advisers and shareholders who have been instrumental in getting us to where we are today. I would also like to take this opportunity to welcome new shareholders to the register and thank them for their support in enabling us to continue to carry out this critical work. I look forward to life as a public company and progressing our development programmes to the next stage with the support of our shareholders." Placing and Subscription Statistics Fundraise Placing Price (per Share) 20 pence Number of Placing Shares 23,968,543 Number of Subscription Shares 13,531,457 Gross proceeds of the Placing (receivable by the Company) GBP4,793,708.60 Gross proceeds of the Subscription (receivable by the GBP2,706,291.40 Company) Total gross proceeds of the Fundraise (receivable by GBP7,500,000 the Company) Estimated net proceeds of the Fundraise available to GBP6,670,000 Company Estimated costs of the Fundraise and Admission GBP830,000 Upon Admission Enlarged Share Capital in issue upon Admission 66,115,201 Number of Ordinary Shares under Option or Warrant following Admission 15,518,832 Fully diluted number of Ordinary Shares following Admission 81,634,033 Unless otherwise stated, the capitalised terms used in this announcement have the same meanings as in the Admission Document. Copies of the Admission Document are available on the Company's website at www.bivictrix.com. ..." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
